The Helsinki Virus (HelVi) Core is a service platform that provides generation of recombinant adeno-associated viral (rAAV) preps for academic and industrial customers in Finland as well as abroad. HelVi uses biosafety level I laboratory equipped with all necessary cell culture equipment such as laminar hoods, incubators, centrifuges and microscopes.
Contact persons: Andrey Anisimov, andrey.anisimov@helsinki.fi; Tanja Laakkonen, tanja.laakkonen@helsinki.fi; Taija Mäkinen, Core director, taija.makinen@helsinki.fi
Location: Biomedicum Helsinki, 5th floor, Haartmaninkatu 8, Meilahti Campus
Please notice: If you use AAV particles purchased from HelVi-AAV in your publication, please acknowledge us in the following way:
“ AAV vectors were produced in AAV Core Unit supported by University of Helsinki (HiLIFE and Research Programs Unit, Faculty of Medicine) and Biocenter Finland”
TISSUE | OPTIMAL SEROTYPE |
CNS | AAV1, AAV2, AAV5, AAV8, AAV9 |
Heart | AAV1, AAV8, AAV9 |
Kidney | AAV8 |
Liver | AAV7, AAV8, AAV9 |
Lung | AAV5, AAV6, AAV9 |
Pancreas | AAV6, AAV8 |
Photoreceptor Cells | AAV2, AAV5, AAV8 |
RPE (Retinal Pigment Epithelium) | AAV1, AAV2, AAV5, AAV8 |
Skeletal Muscle | AAV1, AAV6, AAV7, AAV8, AAV9 |
Pancretic islets derived from iPSC | AAV-KP1 |
Brain endothelial cells | BI30 |
The research infrastructure is supported by University of Helsinki (HiLIFE and Research Programs Unit) and Biocenter Finland. The prices are listed below. For University of Helsinki customers the VAT is 0 %, for the other customers the VAT is 25,5%.
Product name | UH customers | BCF University customer | External customer |
Basic AAV prep (3 ml 2-10e+09 vp/ul) | 752,23 € | 889,52 € | 2 209,17 € |
TAKARA prep (small scale AAV prep for testing) 50-100 ul 2-8e+09 vp/ul | 439,74 € | 510,26 € | 1 507,60 € |
Concentrated AAV prep extra charge ( 0,5-1 ml 1-4 e+10 vp/ul) | 49,89 € | 54,29 € | 270,27 € |
HelVi has several ready AAV preps in storage, which can be mainly used as a negative control in vivo or in vitro. These ready AAV preps * (as listed in the Table below) can be sold in smaller amounts, reducing the price.
Transgene | AAV serotype | Notes |
---|---|---|
Human Serum Albumin (HSA) | AAV9 | |
Empty vector (no transgene) | AAV9 | |
Fc-part of mouse IgG (mFC) | AAV9, AAV2 | Control for Fc-fuced proteins |
EGFP | AAV9, AAV2, AAV8, AAV6 | |
Luciferaasi | AAV9, AAV2, AAV8 | |
LacZ | AAV9 | |
Cre recombinase | AAV9, AAV2, AAV8 | Can be used to cut away loxP flanked DNA sequences |
* For other available AAV preps, not included in the Table, please, send e-mail or call.
Please, check our latest publications, where AAVs produced by our Core, were used:
2023
Li et al. Blockade of VEGFR3 signaling leads to functional impairment of dural lymphatic vessels without affecting autoimmune neuroinflammation. Sci Immunol. 2023 Apr 14;8(82):eabq0375.
Ignatenko O. Mitochondrial dysfunction compromises ciliary homeostasis in astrocytes. J Cell Biol. 2023 Jan 2;222(1):e202203019.
Anisimov, Fang et al. The angiopoietin receptor Tie2 is atheroprotective in arterial endothelium. Nat Cardiovasc Res. 2023 Mar 13;2(3):307-321.
Purhonen et al. Mitochondrial complex III deficiency drives c-MYC overexpression and illicit cell cycle entry leading to senescence and segmental progeria. Nat Commun. 2023 Apr 24;14(1):2356.
2024
Ucar MC et al. Self-organized and directed branching results in optimal coverage in developing dermal lymphatic networks. Nat Commun. 2023 Sep 21;14(1):5878.
Sultan I et al. Contribution of VEGF-B-Induced Endocardial Endothelial Cell Lineage in Physiological Versus Pathological Cardiac Hypertrophy. Circ Res. 2024 May 24;134(11):1465-1482.
Keuters et al. The Impact of VEGF-C-Induced Dural Lymphatic Vessel Growth on Ischemic Stroke Pathology. Transl Stroke Res. 2024 Jun 1. doi: 10.1007/s12975-024-01262-9. Online ahead of print.
Antila et al. Sustained meningeal lymphatic vessel atrophy or expansion does not alter Alzheimer's disease-related amyloid pathology. Nat Cardiovasc Res. 2024 Apr:3:474-491.